MorphoSys AGNASDAQ:MOR
- LAST PRICE18.4100
- TODAY'S CHANGE (%)0.0400 (0.2177%)
- Bid / Lots18.2200/ 1
- Ask / Lots27.6700/ 2
- Open / Previous Close18.2300 / 18.3700
- Day Range
- 52 Week Range
- Volume15,562
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MOR |
|---|---|---|
| 09:32 ET | 3383 | 18.415 |
| 09:45 ET | 1465 | 18.45 |
| 09:50 ET | 200 | 18.48 |
| 11:06 ET | 200 | 18.48 |
| 11:08 ET | 2532 | 18.4 |
| 12:27 ET | 622 | 18.45 |
| 12:38 ET | 454 | 18.45 |
| 01:37 ET | 160 | 18.47 |
| 01:50 ET | 120 | 18.4101 |
| 02:15 ET | 300 | 18.47 |
| 02:20 ET | 100 | 18.44 |
| 02:44 ET | 421 | 18.47 |
| 03:02 ET | 270 | 18.4699 |
| 03:12 ET | 874 | 18.47 |
| 03:30 ET | 342 | 18.47 |
| 03:52 ET | 100 | 18.45 |
| 03:59 ET | 324 | 18.41 |
Jul 17, 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI on Behalf of Shareholders, from 10:51AM ET on Wednesday Jul 17, 2024 by Dow Jones
10:51AM ET on Wednesday Jul 17, 2024 by Dow Jones
Jul 16, 2024
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG -- MOR, from 4:52PM ET on Tuesday Jul 16, 2024 by Dow Jones
4:52PM ET on Tuesday Jul 16, 2024 by Dow Jones
Jul 15, 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI, MGOL on Behalf of Shareholders, from 11:59PM ET on Monday Jul 15, 2024 by Dow Jones
11:59PM ET on Monday Jul 15, 2024 by Dow JonesSHAREHOLDER ALERT: The M&A Class Action Firm Investigates Tender Offer Expiring August 2, 2024, of MorphoSys AG - MOR, from 3:50PM ET on Monday Jul 15, 2024 by Dow Jones
3:50PM ET on Monday Jul 15, 2024 by Dow Jones
Jul 12, 2024
Press Release: MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market, from 4:59PM ET on Friday Jul 12, 2024 by Dow Jones
4:59PM ET on Friday Jul 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MorphoSys AG | 2.8B | -5.4x | --- |
ADMA Biologics Inc | 3.0B | -645.1x | --- |
TG Therapeutics Inc | 3.1B | 93.3x | --- |
Twist Bioscience Corp | 3.3B | -17.3x | --- |
Denali Therapeutics Inc | 3.4B | -24.9x | --- |
Genmab A/S | 18.5B | 23.6x | +22.71% |
Company Information
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Contact Information
- Headquarters
- Semmelweisstr. 7PLANEGG, Germany 82152
- Phone
- ---
- Fax
- 898-992-7222
Executives
- Independent Chairman of the Supervisory Board
- Marc Cluzel
- Chairman of the Management Board, Chief Executive Officer
- Jean-Paul Kress
- Independent Deputy Chairman Member of the Supervisory Board
- George Golumbeski
- Chief Financial Officer, Member of the Executive Committee
- Lucinda Crabtree
- Senior Vice President, Head of Corporate Affairs, Member of the Executive Committee
- Thomas Biegi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8B |
|---|---|
Revenue (TTM) | $220.7M |
Shares Outstanding | 150.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.20 |
EPS | $-3.40 |
Book Value | $0.35 |
P/E Ratio | -5.4x |
Price/Sales (TTM) | 12.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -220.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
